Taysha Gene Therapies (TSHA) reported a net loss of $39.1 million, or $0.10 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported no revenue during the quarter and held $422.8 million in cash and cash equivalents at period-end.
Taysha said its REVEAL pivotal and ASPIRE trials of TSHA-102 for Rett syndrome remain ongoing. The company expects topline data from the REVEAL six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.
- Research and development expense was $28.8 million, compared with $25.7 million a year earlier.
- General and administrative expense was $13.1 million, compared with $8.3 million a year earlier.
- TSHA-102 was generally well tolerated across REVEAL Phase 1/2, pivotal and ASPIRE trials involving 33 patients as of the November 2026 data cutoff, with no severe treatment-related serious adverse events or dose-limiting toxicities reported.
- The company completed a BLA-enabling PPQ manufacturing campaign for TSHA-102 that met predefined product specifications and comparability criteria.
- Taysha expects its current cash resources to support planned operating expenses and capital requirements into the second half of 2028.
$TSHA Insider Trading Activity
$TSHA insiders have traded $TSHA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TSHA stock by insiders over the last 6 months:
- SUKUMAR NAGENDRAN (President and Head of R&D) sold 200,000 shares for an estimated $1,248,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TSHA Hedge Fund Activity
We have seen 135 institutional investors add shares of $TSHA stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MPM BIOIMPACT LLC added 4,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $30,645,000
- WELLINGTON MANAGEMENT GROUP LLP added 3,349,244 shares (+534.7%) to their portfolio in Q2 2026, for an estimated $22,808,351
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,722,165 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $18,537,943
- BLACKROCK, INC. added 2,326,319 shares (+12.7%) to their portfolio in Q2 2026, for an estimated $15,842,232
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,200,695 shares (+inf%) to their portfolio in Q2 2026, for an estimated $14,986,732
- AVORO CAPITAL ADVISORS LLC added 2,188,888 shares (+10.1%) to their portfolio in Q2 2026, for an estimated $14,906,327
- ORBIMED ADVISORS LLC added 2,000,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $13,620,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.